Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 7/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208796 | 0.87 | GRN (0.43) | ALDH1A1EPHX1ACHETSHRHPGD | |
| SCHEMBL7008178 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPK1ALDH1A1EPHX1ACHE | |
| SCHEMBL19727092 | 0.79 | CAD (0.41) | SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8593917 | 0.78 | KMT2A (0.43) | SMN1; SMN2MAPK1ALDH1A1EPHX1ACHE | |
| SCHEMBL31757805 | 0.78 | CYP1A2 (0.57) | SMN1; SMN2ALDH1A1HPGDCYP1A2CYP2C9 | |
| SCHEMBL7006306 | 0.77 | KMT2A (0.49) | SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL14744557 | 0.77 | KMT2A (0.64) | SMN1; SMN2MAPK1ALDH1A1EPHX1ACHE | |
| SCHEMBL6168369 | 0.77 | KMT2A (0.49) | SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL13059741 | 0.77 | CYP1A2 (0.49) | SMN1; SMN2MAPK1ALDH1A1EPHX1ACHE | |
| SCHEMBL8803967 | 0.76 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPK1ALDH1A1EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362209-A1 | PYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170190715-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362209-A1 | PYRIDINE DERIVATIVES | LAP3, PREP, DNPEP | SMN1; SMN2 4624/4885MAPK1 4281/4885ALDH1A1 240/4885 |
| US-20170190715-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | SMN1; SMN2 4567/4885MAPK1 4390/4885ALDH1A1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.